Solid Biosciences to Participate at the SVB Leerink 11th Annual Global Healthcare Conference
Solid Biosciences (Nasdaq: SLDB) announced participation in a fireside chat at the 11th Annual Global Healthcare Conference on February 17, 2022, at 4:20 pm ET. The chat will feature Joel Schneider, PhD, COO, and Carl Morris, PhD, CSO.
A live webcast will be accessible on the company's investor relations website. Solid Biosciences aims to develop transformative treatments for Duchenne muscular dystrophy, focusing on correcting the underlying mutation with gene therapy candidates SGT-001 and SGT-003.
- None.
- None.
CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Joel Schneider, PhD, Chief Operating Officer, and Carl Morris, PhD, Chief Scientific Officer, will participate in a fireside chat at the SVB Leerink 11th Annual Global Healthcare Conference on Thursday, February 17, 2022 at 4:20 pm ET.
A live webcast of this fireside chat will be available on the Company’s investor relations website, under the Events page accessible here: https://investors.solidbio.com/news-and-events/events. A replay will be available on the Company's website following the event.
About Solid Biosciences
Solid Biosciences is a life sciences company focused on advancing transformative treatments to improve the lives of patients living with Duchenne. Disease-focused and founded by a family directly impacted by Duchenne, our mandate is simple yet comprehensive – work to address the disease at its core by correcting the underlying mutation that causes Duchenne with our lead gene therapy candidate, SGT-001, as well as our recently announced next-generation gene therapy candidate, SGT-003. For more information, please visit www.solidbio.com.
Investor Contact:
David Carey
FINN Partners
212-867-1768
David.Carey@finnpartners.com
Caitlin Lowie
Solid Biosciences
607-423-3219
clowie@solidbio.com
Media Contact:
Erich Sandoval
FINN Partners
917-497-2867
Erich.Sandoval@finnpartners.com
FAQ
What is Solid Biosciences' participation in the healthcare conference on February 17, 2022?
Who will represent Solid Biosciences at the SVB Leerink conference?
Where can I watch the Solid Biosciences fireside chat live?
What are the main focuses of Solid Biosciences?
What are the names of Solid Biosciences' gene therapy candidates mentioned in the press release?
